Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Topline data presented from first cohort of phase Ib trial of RGLS-4326

May 4, 2021

FDA approves Farxiga for chronic kidney disease

May 3, 2021

Pooled data from the AURORA and AURA-LV trials across lupus nephritis biopsy classes

April 12, 2021

X-Chem discloses new HAOX1 inhibitors

April 8, 2021

First patient dosed in phase II AFFINITY basket study of atrasentan

April 8, 2021

FDA approves Myrbetriq tablets and granules for neurogenic detrusor overactivity in children

March 26, 2021

New hydroxyacid oxidase 1 inhibitors discovered at OxaluRx

March 18, 2021

Renibus initiates phase II trial of RBT-1 for prevention of AKI

March 12, 2021

Phase III study of sparsentan in FSGS achieves interim proteinuria endpoint

Feb. 2, 2021

Zymso approved in Japan for interstitial cystitis

Jan. 26, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.